Company profile: GENinCode
1.1 - Company Overview
Company description
- Provider of genetic testing solutions for cardiovascular disease risk assessment and prediction, combining genetic and clinical data to guide patient evaluation. Offerings include CARDIO inCode-Score for coronary heart disease, LIPID inCode for hyperlipidemia and familial hypercholesterolemia, SUDD inCode for sudden cardiac death, THROMBO inCode for venous thromboembolism, ROCA for ovarian cancer, and SITAB web portal.
Products and services
- CARDIO inCode-Score: An integrated genetic test assessing coronary heart disease risk by analyzing an individual's genetic profile and combining it with traditional clinical risk factors to deliver advanced clinical information
- THROMBO inCode: A multi-marker genetic test assessing venous thromboembolism risk by analyzing multiple genetic markers, supplying advanced clinical information for practitioner evaluation
- LIPID inCode: A marker-based genetic test evaluating hyperlipidemia and familial hypercholesterolemia risk by analyzing specific genetic markers and integrating clinical data to guide practitioner assessment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GENinCode
Celera
HQ: United States
Website
- Description: Provider of molecular diagnostic products and services that leverage knowledge of human variability to personalize disease management, enabling hospitals and clinical laboratories to detect, characterize, monitor, and select treatment for disease, including genotyping for infections diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celera company profile →
CiVi Biopharma
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development focused on novel cardiovascular therapies, including CiVi 008, an oral PCSK9-targeting treatment to lower LDL cholesterol and prevent atherosclerotic cardiovascular disease, and CiVi 030, an intravenous iloprost formulation for severe frostbite with vasodilator, platelet inhibitor, anti-inflammatory, and anti-fibrotic effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CiVi Biopharma company profile →
Acron Genomics
HQ: United Kingdom
Website
- Description: Provider of novel biotechnology platform development and commercialization in the life sciences, and of the introduction and development of promising new pharmaceutical compounds. U.S. publicly traded (OTC Markets/AGNM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acron Genomics company profile →
RhythMedix
HQ: United States
Website
- Description: Provider of cardiac diagnostics and monitoring solutions, including RhythmStar wearable ECG monitor with built-in 4G cellular connectivity for continuous monitoring and compliance checks, mobile cardiac telemetry, extended wear Holter (3–15 days), Holter monitoring (24–48 hours), event monitoring, and RhythmConnect patient portal to enroll, track, and manage patients, supported by outstanding service, support, and patient care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RhythMedix company profile →
InnovHeart
HQ: Italy
Website
- Description: Provider of transcatheter mitral valve replacement systems to treat patients with mitral valve disease, including the Saturn TMVR System designed for trans-apical or trans-septal delivery. Offers a novel therapeutic system to replace incompetent mitral valves based on safe, effective, and easy-to-use transcatheter technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InnovHeart company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GENinCode
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GENinCode
2.2 - Growth funds investing in similar companies to GENinCode
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GENinCode
4.2 - Public trading comparable groups for GENinCode
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →